Murali Ramachandran

Murali Ramachandran is listed in filings as VP of Research and Development at Kairos Pharma, Ltd.. This profile follows SEC Form 4 activity through Nov 26, 2025, including purchase activity. Recent filings connect the profile to Kairos Pharma, Ltd. (KAPA). The current snapshot covers public activity from Nov 25, 2024 to Nov 26, 2025. Reported amounts are shown as $318. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.